Role of protein kinase C activation in synthesis of complement components C2 and factor B in interferon-gamma-stimulated human fibroblasts, glioblastoma cell line A172 and monocytes.
The synthesis of C2 and factor B, the key components of complement system, is performed by various kinds of cells and is also up-regulated by interferon-gamma (IFN-gamma). By using human fibroblasts, human glioblastoma cell line A172 and monocytes, we investigated the signal-transduction mechanism for IFN-gamma-induced synthesis of C2 and factor B. The C2 and factor B synthesis induced by IFN-gamma in all three cell types was inhibited by a protein kinase C (PKC) inhibitor, 1-(5-isoquinolinyl-sulphonyl)-2-methylpiperazine (H-7). The depletion of PKC in these cell types after treatment with phorbol 12-myristate 13-acetate (PMA) resulted in inhibition of IFN-gamma-induced C2 production. In addition, IFN-gamma treatment elicited a decrease in cytoplasmic PKC in A172 cells, indicating that PKC is activated by IFN-gamma. These results suggest that PKC is crucial for IFN-gamma-induced C2 and factor B synthesis. Northern-blot analysis showed that the effects at H-7 were at least partly mediated by modulation of C2 and factor B mRNA abundance in A172 cells. Since treatment of fibroblasts and A172 cells with IFN-gamma had no effect on intracellular Ca2+ concentration, and since neither EGTA nor nifedipine inhibited C2 or factor B synthesis induced by IFN-gamma, we concluded that intracellular Ca2+ mobilization was not involved in the effect of IFN-gamma. In addition, genistein, herbimycin A and N-(6-aminohexyl)-5-chloro-1-naphthalene-sulphonamide (W-7) had no inhibitory effect on IFN-gamma-mediated action in any of the three cell types, which suggests that IFN-gamma acts independently of tyrosine kinases and calmodulin-dependent protein kinases.
First Department of Internal Medicine, School of Medicine, Ehime University, Japan.
I
I
Watanabe
T
T
Horiuchi
S
S
Fujita
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D016227:Benzoquinones; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D003175:Complement C2 / Q000096:biosynthesis* / Q000235:genetics; D011415:Complement Factor B / Q000096:biosynthesis* / Q000235:genetics; D004789:Enzyme Activation; D005347:Fibroblasts; D019833:Genistein; D005909:Glioblastoma; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D007529:Isoflavones / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D047029:Lactams, Macrocyclic; D009000:Monocytes; D010879:Piperazines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011809:Quinones / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D017471:Receptors, Interferon / Q000378:metabolism; D017828:Rifabutin / Q000031:analogs & derivatives; D015398:Signal Transduction / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015854:Up-Regulation; D000096743:Interferon gamma Receptor
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D016227:Benzoquinones; D002118:Calcium; D003175:Complement C2; D011415:Complement Factor B; D019833:Genistein; D007371:Interferon-gamma; D007529:Isoflavones; D007546:Isoquinolines; D047029:Lactams, Macrocyclic; D010879:Piperazines; D011493:Protein Kinase C; D011505:Protein-Tyrosine Kinases; D011809:Quinones; D012333:RNA, Messenger; D017471:Receptors, Interferon; D017828:Rifabutin; D013449:Sulfonamides; D013755:Tetradecanoylphorbol Acetate; D000096743:Interferon gamma Receptor; C017967:W 7; C020754:herbimycin